Avenue Therapeutics – Consensus Indicates Potential 51.3% Upside

Broker Ratings

Avenue Therapeutics with ticker code (ATXI) now have 2 analysts in total covering the stock. The consensus rating is ‘Buy’. The target price ranges between 12 and 6 and has a mean target at 9. Given that the stocks previous close was at 5.95 this indicates there is a potential upside of 51.3%. The day 50 moving average is 4.34 and the 200 day moving average is 7.91. The market cap for the company is $100m. Visit the company website at: http://www.avenuetx.com

Avenue Therapeutics, a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was founded in 2015 and is based in New York, New York. Effective as of December 31, 2019, Avenue Therapeutics operates as a subsidiary of InvaGen Pharmaceuticals

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index